Germouty J
Rev Pneumol Clin. 1986;42(4):207-13.
A new immunomodulator, SLO4 oral drops, was tested for treatment and prevention of recurrent respiratory infections in a double-blind, drug versus placebo trial conducted in 60 adults with chronic bronchitis or asthma. This agent brought about a highly significant reduction in the frequency and duration of infectious episodes, as well as a decrease in antibiotic consumption and lost work time. Well tolerated from the clinical and laboratory points of view, it proved remarkably effective. It has been hypothesized that induction of interferon may account for the excellent clinical results obtained with SLO4, and numerous authors regard this compound as one of the basic keys to regulation of immune reactivity. Pharmacological trials under way with SLO4 should help answer this question.
一种新型免疫调节剂SLO4口服滴剂，在一项针对60名患有慢性支气管炎或哮喘的成年人进行的双盲、药物与安慰剂对照试验中，被用于测试其对复发性呼吸道感染的治疗和预防效果。该药物使感染发作的频率和持续时间大幅降低，同时抗生素消耗量减少，误工时间缩短。从临床和实验室角度来看，它耐受性良好，证明非常有效。据推测，干扰素的诱导作用可能是SLO4取得优异临床效果的原因，许多作者将这种化合物视为调节免疫反应性的关键因素之一。正在进行的SLO4药理学试验应有助于回答这个问题。
